01 March, 2021
Immunotherapies are treatments that stimulate or supress the immune system to prevent or manage disease. This article the final in a six-part series discusses their history and development, exploring how they are used to treat cancers, autoimmune disease and allergy
Abstract
This article, the final in a six-part series about the lymphatic system, discusses the history and development of immunotherapy. It highlights a number of immunotherapies that are available for different health conditions – including cancer, autoimmune disease and allergy – and explores how they function and interact with the immune system.
Citation: Knight J, Nigam Y (2021) The lymphatic system 6: the history and function of immunotherapies.
LUNGevity Foundation Amplifies Efforts to Improve Lung Cancer Patient Access to Comprehensive Biomarker Testing through New Awareness Campaign
New campaign aims to ensure there is No One Missed in receiving comprehensive biomarker testing and a fully informed diagnosis for the appropriate treatment
News provided by
Share this article
Share this article
WASHINGTON, Feb. 18, 2021 /PRNewswire/ LUNGevity Foundation will be launching a new lung cancer campaign called
No One Missed, created to drive essential comprehensive biomarker testing in non-small cell lung cancer (NSCLC). Guideline-recommended comprehensive biomarker testing can reveal vital information to help identify the appropriate individualized treatment plan for each NSCLC patient.
LUNGevity Foundation Amplifies Efforts to Improve Lung Cancer Patient Access to Comprehensive Biomarker Testing through New Awareness Campaign prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
THOUSAND OAKS, Calif., Feb. 16, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for sotorasib for the treatment of patients with
KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following at least one prior systemic therapy.
The FDA grants Priority Review to applications for medicines that offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. Based on the Priority Review designation, the Prescription Drug User Fee Action (PDUFA) date for sotorasib is Aug. 16, 2021, which is four months earlier than the standard review cycle.
– Results of phase 2 trial show CABOMETYX significantly improved progression-free survival versus current guideline-preferred therapy –
– Data to be presented during the 2021. | February 16, 2021